ASPR announces investment to increase domestic production of essential drugs
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir, also known as Tamiflu. The investment is ASPR’s first under the Department of Health and Human Services-designated Defense Production Act Title III program, which is intended to strengthen the U.S. public health supply chain and reduce reliance on foreign resources by increasing the domestic production of essential medications and their active pharmaceutical ingredients. ASPR said Manus Bio Inc., based in Waltham, Mass., will expand its facilities in Augusta, Ga., to produce shikimic acid, a key ingredient for the drug.
Related News Articles
Headline
Two new AHA briefs outline field-tested strategies on strengthening supply chain resilience and hospital capacity readiness to maintain quality of care during…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…